Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index; 27 of the 69 sources its claims cite were checked for support.

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Open access

Abstract

Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after two step-up priming doses. After six cycles, persistent responders switched to biweekly dosing. Results from cohort A, which enrolled patients without prior BCMA-directed therapy (n = 123) are reported. The primary endpoint of confirmed objective response rate (ORR) by blinded independent central review was met with an ORR of 61.0% (75/123); 35.0% ≥complete response. Fifty responders switched to biweekly dosing, and 40 (80.0%) improved or maintained their response for ≥6 months. With a median follow-up of 14.7 months, median duration of response, progression-free survival and overall survival (secondary endpoints) have not been reached. Fifteen-month rates were 71.5%, 50.9% and 56.7%, respectively. Common adverse events (any grade; grade 3-4) included infections (69.9%, 39.8%), cytokine release syndrome (57.7%, 0%), anemia (48.8%, 37.4%), and neutropenia (48.8%, 48.8%). With biweekly dosing, grade 3-4 adverse events decreased from 58.6% to 46.6%. Elranatamab induced deep and durable responses with a manageable safety profile. Switching to biweekly dosing may improve long-term safety without compromising efficacy. ClinicalTrials.gov identifier: NCT04649359 .

Overview

CoChat Summary

TL;DR

Elranatamab monotherapy in the phase 2 MagnetisMM-3 cohort A produced a 61.0% confirmed objective response rate in 123 patients with relapsed or refractory multiple myeloma who had no prior BCMA-directed therapy. Responses were often deep and durable, with 35.0% achieving ≥CR, 60.5% of those ≥CR being MRD-negative, and safety being manageable though infections, CRS, and cytopenias were common.

Key findings

  • In 123 treated patients, the confirmed objective response rate by blinded independent central review was 61.0% (75/123; 95% CI 51.8–69.6).
  • Deep responses were frequent: 35.0% achieved ≥CR, 56.1% achieved VGPR or better, and among patients with ≥CR and evaluable MRD (n = 29), 89.7% were MRD-negative, corresponding to 60.5% of all patients with ≥CR.
  • With median follow-up of 14.7 months, median duration of response, progression-free survival, and overall survival were not reached; 15-month estimates were 71.5% for maintaining response, 50.9% for PFS, and 56.7% for OS.
  • Among 50 responders who switched to biweekly dosing at least 6 months before data cutoff, 80.0% maintained or improved response ≥6 months after the switch, and 40.0% deepened response, including 38.0% who improved to ≥CR.
  • Safety: all 123 patients had treatment-emergent AEs; 70.7% had grade 3 or 4 events. Common AEs included infections (69.9%; 39.8% grade 3–4), CRS (57.7%; 0% grade 3–4), anemia (48.8%; 37.4% grade 3–4), and neutropenia (48.8%; 48.8% grade 3–4).

Methods

  • Ongoing multicenter, open-label, single-arm phase 2 MagnetisMM-3 study of elranatamab monotherapy in relapsed or refractory multiple myeloma; this report covers cohort A (no prior BCMA-directed therapy), with 123 enrolled and treated patients across 47 sites in 10 countries.
  • Eligible patients were adults with measurable disease, ECOG ≤2, adequate organ function, and disease refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 antibody; treatment was subcutaneous elranatamab 76 mg weekly after 12 mg and 32 mg step-up doses, with responders switching to biweekly dosing after 6 cycles if PR or better persisted for at least 2 months.
  • Primary endpoint was confirmed ORR by BICR; secondary endpoints included CR rate, MRD negativity, TTR, DOR, PFS, OS, safety, pharmacokinetics, and immunogenicity; analyses were descriptive with Kaplan–Meier methods for time-to-event outcomes.

Limitations

  • The paper states the main limitations are the single-arm design, lack of direct comparison with other treatments, small sample sizes in some subgroups, and the need for longer follow-up to confirm DOR, PFS, and OS benefits.
  • Evident from the text: results for biweekly dosing are not from a randomized QW comparator, so the authors note the safety change after switching cannot be cleanly interpreted.
  • Evident from the text: the cohort reported here excludes patients with prior BCMA-directed therapy, so the findings do not address that population.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02528-9

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 CONSORT diagram of MagnetisMM-3.
Fig. 1 CONSORT diagram of MagnetisMM-3.CC BY · PubMed Central
Fig. 2 Response to elranatamab in patients with relapsed or refractory multiple myeloma. a, Stacked bar graph illustrating the rate of sCR, CR, VGPR and PR in 123 patients who were treated with elranatamab. Responses were assessed by BICR. b, Forest plot illustrating the ORR by BICR in subgroups. Blue squares denote ORR, and whiskers indicate 95% CIs. c, Swimmer plot showing responses over time in 75 patients who had a response following elranatamab treatment. Responses were assessed by BICR, whereas treatment decisions, including switch to Q2W dosing, were made by the investigator. EOT, end of treatment; MR, minimal response; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response.
Fig. 2 Response to elranatamab in patients with relapsed or refractory multiple myeloma. a, Stacked bar graph illustrating the rate of sCR, CR, VGPR and PR in 123 patients who were treated with elranatamab. Responses were assessed by BICR. b, Forest plot illustrating the ORR by BICR in subgroups. Blue squares denote ORR, and whiskers indicate 95% CIs. c, Swimmer plot showing responses over time in 75 patients who had a response following elranatamab treatment. Responses were assessed by BICR, whereas treatment decisions, including switch to Q2W dosing, were made by the investigator. EOT, end of treatment; MR, minimal response; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response.CC BY · PubMed Central
Fig. 3 Kaplan–Meier analysis of DOR, PFS and OS. a, DOR in 75 patients who had an objective response (OR; red line) and in 43 patients who had CR or better (≥CR) (blue line). b, PFS in the overall population (red line) and in 43 patients who had ≥CR (blue line). c, OS in the overall population (red line) and in 43 patients who had ≥CR (blue line). Tick marks indicate censored data. NE, not estimable.
Fig. 3 Kaplan–Meier analysis of DOR, PFS and OS. a, DOR in 75 patients who had an objective response (OR; red line) and in 43 patients who had CR or better (≥CR) (blue line). b, PFS in the overall population (red line) and in 43 patients who had ≥CR (blue line). c, OS in the overall population (red line) and in 43 patients who had ≥CR (blue line). Tick marks indicate censored data. NE, not estimable.CC BY · PubMed Central
Fig. 4 CRS profile of patients who received the 12/32-mg two-step-up priming regimen. CRS experienced by each of the 119 patients who received the 12/32-mg two step-up priming regimen is shown by grade after each dose received. Grade 0 denotes no CRS.
Fig. 4 CRS profile of patients who received the 12/32-mg two-step-up priming regimen. CRS experienced by each of the 119 patients who received the 12/32-mg two step-up priming regimen is shown by grade after each dose received. Grade 0 denotes no CRS.CC BY · PubMed Central
Extended Data Fig. 1 Objective response rate and duration of response (DOR) by blinded independent central review (BICR) in select poor prognosis subgroups. a, Stacked bar graphs illustrating the rate of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) in patients with or without extramedullary disease (EMD) at baseline, with R-ISS disease stage I-II or III, and with or without penta-refractory disease. Responses were assessed by BICR. b, Kaplan-Meier analysis of the DOR in patients with or without EMD. c, Kaplan-Meier analysis of the DOR in patients with R-ISS disease stage I-II or III. d, Kaplan-Meier analysis of the DOR in patients with or without penta-refractory disease. NE, not estimable; penta-ref, penta-refractory; R-ISS, Revised International Staging System.
Extended Data Fig. 1 Objective response rate and duration of response (DOR) by blinded independent central review (BICR) in select poor prognosis subgroups. a, Stacked bar graphs illustrating the rate of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) in patients with or without extramedullary disease (EMD) at baseline, with R-ISS disease stage I-II or III, and with or without penta-refractory disease. Responses were assessed by BICR. b, Kaplan-Meier analysis of the DOR in patients with or without EMD. c, Kaplan-Meier analysis of the DOR in patients with R-ISS disease stage I-II or III. d, Kaplan-Meier analysis of the DOR in patients with or without penta-refractory disease. NE, not estimable; penta-ref, penta-refractory; R-ISS, Revised International Staging System.CC BY · PubMed Central
Extended Data Fig. 2 Treatment-emergent adverse events (TEAEs) up to 3 months before and after switching to once every 2 weeks (Q2W) dosing. TEAEs occurring in ≥20% of patients at the level of SOC and in ≥10% of patients at the level of PT in up to 3 months before or after switching to Q2W dosing are reported in the 58 patients who switched to Q2W dosing. Asterisks (*) indicate a difference ≥10% in TEAE incidence after switching to Q2W dosing. COVID, coronavirus disease; PT, preferred terms; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SOC, system organ class.
Extended Data Fig. 2 Treatment-emergent adverse events (TEAEs) up to 3 months before and after switching to once every 2 weeks (Q2W) dosing. TEAEs occurring in ≥20% of patients at the level of SOC and in ≥10% of patients at the level of PT in up to 3 months before or after switching to Q2W dosing are reported in the 58 patients who switched to Q2W dosing. Asterisks (*) indicate a difference ≥10% in TEAE incidence after switching to Q2W dosing. COVID, coronavirus disease; PT, preferred terms; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SOC, system organ class.CC BY · PubMed Central

Verification

Claims the paper makes

13 Valid · 1 Not valid · 10 Not checked · 88 Own results and interpretations

53 more claims · 2 with their cited sources checked

Create a free account to see all 112 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 21
  • It may state two separate claims as one. 42

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Cited by

See all 664

Metadata

Authors
Lesokhin, A. M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Miles Prince, H., Niesvizky, R., Rodrίguez-Otero, P., Martinez-Lopez, J., Koehne, G., Touzeau, C., Jethava, Y., Quach, H., Depaus, J., Yokoyama, H., Gabayan, A. E., Stevens, D. A., Nooka, A. K., Manier, S., Raje, N., Iida, S., Raab, M.-S., Searle, E., Leip, E., Sullivan, S. T., Conte, U., Elmeliegy, M., Czibere, A., Viqueira, A., & Mohty, M.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • University of Iowa (US)
  • Hôpital Saint-Louis (FR)
  • University of Calgary (CA)
  • Centre Hospitalier Universitaire de Nantes (FR)
  • The University of Melbourne (AU)
  • UCLouvain (BE)
  • Tohoku University (JP)
  • Beverly Hills Cancer Center (US)
  • Norton Healthcare (US)
  • Winship Cancer Institute (US)
  • Inserm (FR)
  • Harvard University (US)
  • Nagoya City University (JP)
  • University Hospital Heidelberg (DE)
  • University of Manchester (GB)
  • Pfizer (United States) (US)
  • Pfizer (Spain) (ES)
Corresponding author
Lesokhin, Alexander M.
Venue
Nature Medicine
Published
2023-08-15
Volume
29
Issue
9
Pages
2259-2267
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4385839624
Cited by
664
References
38
Citations by year
2026: 213 · 2025: 242 · 2024: 181 · 2023: 28
FWCI
136.62
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion, other-oa)
  • HAL (submittedVersion)
  • Digital Access to Libraries (submittedVersion, other-oa)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • Scholarly Commons - Baptist Health South Florida (Baptist Health South Florida) (submittedVersion, cc-by)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Keywords
elranatamab, relapsed/refractory multiple myeloma, BCMA-CD3 bispecific antibody, BCMA, subcutaneous dosing, biweekly dosing, objective response rate, progression-free survival, overall survival, cytokine release syndrome, adverse events
MeSH terms
Progression-Free Survival, Humans, Multiple Myeloma, Remission Induction, B-Cell Maturation Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. https://app.cochat.ai/papers/10.1038/s41591-023-02528-9
The paper
Lesokhin, A. M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Miles Prince, H., Niesvizky, R., Rodrίguez-Otero, P., Martinez-Lopez, J., Koehne, G., Touzeau, C., Jethava, Y., Quach, H., Depaus, J., Yokoyama, H., Gabayan, A. E., Stevens, D. A., Nooka, A. K., Manier, S., Raje, N., . . . Mohty, M. (2023). Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nature Medicine. https://doi.org/10.1038/s41591-023-02528-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.